CB -- Use of the Zilver PTX (paclitaxel) drug-eluting stent (Cook Medical) in comparison to bare-metal stents (BMS) reduced restenosis rates by 63 percent, and proved to have better outcomes than primary percutaneous transluminal angioplasty (PTA) for femoropopliteal peripheral artery disease (PAD) patients, according to the results of the Zilver PTX late-breaking clinical trial presented Sept. 24 at the 22nd annual Transcatheter Cardiovacular Therapeutics (TCT) scientific meeting.
